Mucormycosis Leading to Cerebral Edema and Cerebellar Tonsillar Herniation after Allogeneic Bone Marrow Transplant: A Case Report by Chetan Jeurkar, Lauren Margetich, Ziver Sahin

“…Mucormycosis following hematopoietic stem cell transplant (HSCT) carries a very high mortality rate. …”
Get full text

Fludarabine/Cyclophosphamide Conditioning Regimen in Aplastic Anemia Patients Receiving Matched-Sibling Donor Transplant Is Non-inferior to ATG/Cyclophosphamide: A Single-Center Ex... by Uzma Zaidi, Mushkbar Fatima, Shafaq Abdul Samad, Kashif Shafique, Hira Fatima Waseem, Tasneem Farzana, Tahir Sultan Shamsi

“…The successful outcome of allogeneic hematopoietic stem cell transplant (HSCT) in aplastic anemia patients is driven by suitable donor selection, appropriate conditioning regimen, early intervention, and optimal supportive care after transplant. …”
Get full text

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-an... by Yin-Che Wang, Cheng-Hsien Lin, Yu-Chen Su, Chieh-Lin Jerry Teng

“…The primary endpoints were response rates after induction therapy and the incidence of a need for autologous hematopoietic stem cell transplantion (auto-HSCT) between the groups. …”
Get full text

A Novel Severity Score Index for Febrile Neutropenic Patients with Colorectal Diseases by Camila Perazzoli, Rogério S. Parra, Marley R. Feitosa, Enrico Sfoggia, Belinda Pinto Simões, José J. R. Rocha, Omar Féres

“…This was a case series study analyzing the medical records of 897 patients admitted to the Hematology and Hematopoietic Stem Cell Transplant Unit in a university hospital between the years 2008 and 2013. …”
Get full text

Effective gene therapy for metachromatic leukodystrophy achieved with minimal lentiviral genomic integrations by Lucas Tricoli, Sunetra Sase, Julia L. Hacker, Vi Pham, Maxwell Chappell, Laura Breda, Stephanie N. Hurwitz, Naoto Tanaka, Carlo Castruccio Castracani, Amaliris Guerra, Zhongqi Hou, Lars Schlotawa, Karthikeyan Radhakrishnan, Matthew Hogenauer, Aoife Roche, John Everett, Frederic Bushman, Peter Kurre, Rebecca Ahrens-Nicklas, Laura A. Adang, Adeline L. Vanderver, Stefano Rivella

“…Combined autologous hematopoietic stem cell transplantion (HSCT) with lentiviral (LV)-based gene therapy has great potential to treat MLD. …”
Get full text

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV s... by Muhit Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Ying Chen, Alejandra Nieto, Fatih Demirkan, Pau Montesinos, Fevzi Altuntas

“…Previous studies reported higher rates of post– hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome (SOS) in patients receiving InO versus chemotherapy prior to HSCT. …”
Get full text

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia by Marlise R. Luskin, Shai Shimony, Julia Keating, Eric S. Winer, Jacqueline S. Garcia, Richard M. Stone, Elias Jabbour, Yael Flamand, Kristen Stevenson, Jeremy Ryan, Zhihong Zeng, Anthony Letai, Marina Konopleva, Nitin Jain, Daniel J. DeAngelo

“…All patients in CR bridged to hematopoietic stem cell transplant (n = 9) or completed protocol (n = 1). …”
Get full text

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phas... by Jorge E. Cortes, Gail J. Roboz, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, P. Brent Ferrell, Jay Yang, Eunice S. Wang, William G. Blum, Alice Mims, Hua Tian, Aaron Sheppard, Stéphane de Botton, Pau Montesinos, Antonio Curti, Justin M. Watts, the Olutasidenib Combination Therapy Study Group

“…Most patients (83%) had 2 + prior regimens, including a hypomethylating agent in 40%, IDH1 inhibitor therapy in 31% (olutasidenib in 24%), and hematopoietic stem cell transplant in 10%. Cytogenetic risk was intermediate in 72%, poor in 18% and unknown in 10%. …”
Get full text